Free Trial

InMode (INMD) Competitors

InMode logo
$15.16 -0.06 (-0.36%)
Closing price 07/3/2025 03:31 PM Eastern
Extended Trading
$15.16 +0.01 (+0.03%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INMD vs. NVST, PRCT, LIVN, WRBY, NVCR, LMAT, EYE, ENOV, CNMD, and AORT

Should you be buying InMode stock or one of its competitors? The main competitors of InMode include Envista (NVST), PROCEPT BioRobotics (PRCT), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), and Artivion (AORT). These companies are all part of the "medical equipment" industry.

InMode vs. Its Competitors

Envista (NYSE:NVST) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Envista currently has a consensus target price of $20.23, indicating a potential downside of 0.78%. InMode has a consensus target price of $18.54, indicating a potential upside of 22.35%. Given InMode's higher probable upside, analysts clearly believe InMode is more favorable than Envista.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envista
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.33
InMode
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13

InMode has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.51B1.38-$1.12B-$6.53-3.12
InMode$394.82M2.43$181.27M$2.336.50

In the previous week, Envista had 3 more articles in the media than InMode. MarketBeat recorded 5 mentions for Envista and 2 mentions for InMode. InMode's average media sentiment score of 1.59 beat Envista's score of 1.03 indicating that InMode is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Envista
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InMode
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

68.0% of InMode shares are owned by institutional investors. 1.3% of Envista shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Envista has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, InMode has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.

InMode has a net margin of 44.79% compared to Envista's net margin of -44.90%. InMode's return on equity of 17.17% beat Envista's return on equity.

Company Net Margins Return on Equity Return on Assets
Envista-44.90% 4.07% 2.25%
InMode 44.79%17.17%15.20%

Summary

InMode beats Envista on 11 of the 17 factors compared between the two stocks.

Get InMode News Delivered to You Automatically

Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INMD vs. The Competition

MetricInModeMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$958.25M$10.52B$5.56B$9.05B
Dividend YieldN/A2.07%5.24%3.99%
P/E Ratio6.5011.3219.9620.26
Price / Sales2.4329.81419.56119.26
Price / Cash8.3123.9726.2128.59
Price / Book1.503.668.035.65
Net Income$181.27M$235.43M$3.18B$249.15M
7 Day Performance6.80%2.15%2.93%3.28%
1 Month Performance7.03%1.07%1.72%3.95%
1 Year Performance-12.75%-10.17%34.39%20.98%

InMode Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INMD
InMode
3.3351 of 5 stars
$15.16
-0.4%
$18.54
+22.3%
-12.8%$958.25M$394.82M6.50480
NVST
Envista
3.7777 of 5 stars
$19.58
-0.5%
$20.23
+3.3%
+24.3%$3.32B$2.51B-3.0012,300News Coverage
PRCT
PROCEPT BioRobotics
2.4315 of 5 stars
$57.60
+1.2%
$90.00
+56.3%
-8.8%$3.19B$224.50M-33.88430News Coverage
LIVN
LivaNova
3.219 of 5 stars
$45.02
-1.6%
$59.29
+31.7%
-12.1%$2.45B$1.25B-11.012,900News Coverage
Positive News
WRBY
Warby Parker
2.1868 of 5 stars
$21.94
+0.2%
$22.88
+4.3%
+41.5%$2.29B$771.32M-182.833,780
NVCR
NovoCure
3.6096 of 5 stars
$17.80
-1.1%
$32.83
+84.5%
+5.5%$1.98B$605.22M-11.791,488
LMAT
LeMaitre Vascular
2.4353 of 5 stars
$83.05
+0.6%
$97.83
+17.8%
+1.5%$1.88B$219.86M41.94490
EYE
National Vision
2.6285 of 5 stars
$23.01
-0.7%
$18.67
-18.9%
+94.9%$1.82B$1.85B-69.7313,411News Coverage
ENOV
Enovis
3.5822 of 5 stars
$31.36
-1.3%
$58.00
+84.9%
-25.0%$1.79B$2.11B-2.257,367Positive News
CNMD
CONMED
4.5819 of 5 stars
$52.10
-0.1%
$62.20
+19.4%
-21.1%$1.61B$1.31B13.713,900
AORT
Artivion
2.482 of 5 stars
$31.17
-0.1%
$32.00
+2.7%
+21.7%$1.33B$388.54M-62.341,600

Related Companies and Tools


This page (NASDAQ:INMD) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners